- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11. | TETRATHERIX LIMITED: Notice of Escrow Release | - | ASX | ||
| 10.11. | TETRATHERIX LIMITED: Results of Annual General Meeting | 1 | ASX | ||
| 09.11. | TETRATHERIX LIMITED: 2025 AGM Chair and CEO Address | - | ASX | ||
| 26.10. | TETRATHERIX LIMITED: Q1FY26 Quarterly Activities Report/Appendix 4C | - | ASX | ||
| TETRATHERIX Aktie jetzt für 0€ handeln | |||||
| 13.10. | TETRATHERIX LIMITED: Tutela Update | - | ASX | ||
| 09.10. | TETRATHERIX LIMITED: 2025 Notice of Annual General Meeting | - | ASX | ||
| 08.09. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | 4 | ASX | ||
| 05.09. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX | ||
| 29.08. | TETRATHERIX LIMITED: Notice of Escrow Release | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: 2025 Financial Results Investor Webinar | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: 2025 Financial Results Investor Presentation | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: 2025 Financial Results Announcement | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: Appendix 4E and 2025 Annual Report | - | ASX | ||
| 21.08. | TETRATHERIX LIMITED: Notification regarding unquoted securities - TTX | - | ASX | ||
| 14.08. | Recent ASX debutant Tetratherix locks in A$3.3M gov't grant for healtech | 3 | The Market Herald Australia | ||
| 14.08. | TETRATHERIX LIMITED: Australian Government grant to co-fund strategic program | 1 | ASX | ||
| 22.07. | TETRATHERIX LIMITED: Q4FY25 Quarterly Activities Report/Appendix 4C | - | ASX | ||
| 11.07. | TETRATHERIX LIMITED: Notification regarding unquoted securities - TTX | - | ASX | ||
| 07.07. | Dr Boreham's Crucible: ASX newbie Tetratherix plays it slow and steady | 3 | Stockhead |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 40,390 | 0,00 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| NUVALENT | 109,06 | -0,70 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,330 | 0,00 % | Vera Therapeutics: Aktie laut Analysten unterbewertet - starkes Potenzial im IgAN-Markt | ||
| QIAGEN | 41,775 | -0,04 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,59 | +0,06 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| OLEMA PHARMACEUTICALS | 28,110 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 188,52 | +2,32 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| ADMA BIOLOGICS | 19,150 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| IMMUNOVANT | 23,700 | 0,00 % | Immunovant, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 25,030 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 21,180 | +1,83 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| TREVI THERAPEUTICS | 13,295 | 0,00 % | Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook | ||
| ARCELLX | 73,24 | +0,33 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| NURIX THERAPEUTICS | 17,200 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 30,950 | 0,00 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week |
Das Unternehmen TETRATHERIX LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TETRATHERIX LIMITED finden Sie auf Wallstreet Online.